Tivdak (tisotumab vedotin-tftv)

[indications for Tivdak]
Tivdak is used to treat adult patients with recurrent or metastatic cervical cancer during or after chemotherapy. This indication is approved according to the tumor response rate and response persistence acceleration. The continued approval of this indication may depend on the verification and description of clinical benefits in confirmatory trials.

[Recommended dosage and administration method of Tivdak]
1. Recommended dosage
The recommended dose of Tivdak is 2mg/kg (the maximum dose is 200mg for patients ≥100kg), once every 3 weeks, and every time it is infused intravenously for more than 30 minutes, until the condition worsens or unacceptable toxicity appears.
2. Pre-medication and necessary eye care
Follow the following suggestions to reduce the risk of adverse eye reactions.
Ophthalmic examination: Ophthalmic examination, including vision examination and slit lamp examination, is conducted at baseline, before each administration and when there is clinical instruction.
Topical corticosteroid eye drops: All changes to the initial prescription and any corticosteroid drugs should be made only after slit lamp examination. Drop a drop in each eye before each infusion. Instruct patients to continue to drop eye drops in each eye according to the prescription within 72 hours after each infusion.
Eye drops of local vasoconstrictor: use in each eye immediately before each infusion.
Cold compress: use a cold compress bag when transfusing Tivdak.
Topical lubricating eye drops: instruct patients to use them during treatment and within 30 days after the last dose of Tivdak.
Contact lenses: Patients are advised to avoid wearing contact lenses unless their ophthalmologist recommends wearing contact lenses throughout the treatment.

[Adverse reaction of Tivdak]
The most common (≥25%) adverse reactions (including laboratory abnormalities) are decreased hemoglobin, fatigue, lymphopenia, nausea, peripheral neuropathy, alopecia, nosebleed, conjunctival adverse reactions, hemorrhage, leukopenia, increased creatinine, dry eye, increased international standardized ratio of prothrombin, prolonged activation of partial thromboplastin, diarrhea and rash.

Note: If there is any new packaging for drugs, the new packaging shall prevail. The above information comes from the Internet or translated by student volunteers in medical colleges and universities (if there are any mistakes or omissions, please help me to correct them). It is for internal discussion of medical staff only, without any basis for medication. Please consult the attending physician for specific medication guidelines.